Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
OBJECTIVE
This study was performed to elucidate whether evaluating the liver surface, edge, and texture by high-resolution ultrasonography is useful for predicting the occurrence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-associated chronic liver diseases (CLDs)


METHODS
The integrated fibrosis stage (a comprehensive value of scores for liver edge, surface, and texture) of 337 patients with HCV-associated CLDs was evaluated, at entry, by ultrasonography (US), as a US score. The patients were followed up prospectively (mean observation period was 16.4 months; range 2.8-36.2 months) for the occurrence of HCC by US or helical CT at 3-month intervals. A total of 140 patients received interferon therapy, and the occurrence of HCC was compared between those with and without interferon therapy


RESULTS
The annual incidence of HCC was 1.1, 5.5, and 10.2% in low, middle, and high US score groups, respectively. Univariate analysis showed that age, serum levels of total bilirubin, alpha-fetoprotein (AFP), platelet count, albumin, total cholesterol, and the US score were associated with HCC occurrence in the patients. A multivariate proportional hazard model revealed that only the middle and high US scores (p = 0.0922, hazard ratio 4.006, 95% CI 0.796-20.153 and p = 0.008, hazard ratio 7.991, 95% CI 1.721-37.10, respectively) and elevated AFP (p = 0.031, hazard ratio 2.774, CI 1.097-7.014) were independently associated with HCC occurrence. Our US scoring based on evaluation of the liver surface, edge, and texture was clearly and strongly associated with the occurrence of HCC in patients with HCV-associated CLDs, and with the higher occurrence rate of HCC in patients with higher US scores


CONCLUSIONS
Thus, US is a good tool for evaluating the fibrosis stage of the liver, and may therefore be useful in designing an optimum follow-up interval for each patient with HCV-associated CLD.
Clinical Laboratory, National Hospital Organization (NHO) Ureshino Medical Center, 2436 Shimojyukuhei, Ureshino, Saga, 843-0393, Japan. nishiuraecho@yahoo.co.jp.|Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan. nishiuraecho@yahoo.co.jp.
Tetsuya
T
Nishiura
Clinical Laboratory, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Hideaki
H
Watanabe
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Hepatology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Koji
K
Yano
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Clinical Laboratory, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Masahiro
M
Ito
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Hepatology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Seigo
S
Abiru
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Radiology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Hepatology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Toshifumi
T
Fujimoto
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Hepatology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Atsumasa
A
Komori
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Hepatology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Hiroshi
H
Yatsuhashi
Department of Radiology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Yojiro
Y
Matsuoka
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.|Department of Hepatology, National Hospital Organization (NHO) Nagasaki Medical Center, Ōmura, Nagasaki, 856-8562, Japan.
Hiromi
H
Ishibashi
Fibrosis; Hepatitis C virus; Hepatocellular carcinoma; High and low-frequency probe; US score